Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures

Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures

May 20, 2025

Philips Launches Trial to Study Ultra-low X-ray in Coronary Procedures

Primary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance.

Trial seeks to demonstrate benefit of ultra-low dose X-ray technology - Cardiovascular News

Javier Escaned: “The ability to reduce radiation exposure without compromising procedural performance is a key priority in interventional cardiology” Royal Philips has announced the launch of the RADIQAL trial, a multicentre, randomised study seeking to demonstrate that the company’s new ultra-low dose technology can reduce overall patient radiation dose without affecting coronary procedure performance. The trial will enrol 824 coronary artery d…

Philips Launches RADIQAL Study For Ultra-low X-ray Technology

This multicenter, randomized study, sponsored by Philips will enroll 824 coronary artery disease patients across 6 hospitals in Spain, Czech Republic and the US. The first patient in the study was enrolled at Aarhus University Hospital, Denmark.